AngioLab, Inc. Logo

AngioLab, Inc.

Develops anti-angiogenic therapeutics and foods for angiogenesis-related diseases.

251280 | KO

Overview

Corporate Details

ISIN(s):
KR7251280004
LEI:
Country:
South Korea
Address:
대전광역시 유성구 테크노3로 65, 대전광역시
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

AngioLab, Inc. is a biotechnology company established in 1999 that specializes in the research and development of therapeutics based on angiogenesis inhibition. The company develops pharmaceuticals and health functional foods designed to treat a variety of angiogenesis-related diseases. Its core technology focuses on the discovery and application of anti-angiogenic and matrix metalloproteinase (MMP) inhibitors. AngioLab manages a pipeline of drug candidates, advancing them through clinical trials to create novel treatments for conditions driven by abnormal blood vessel formation.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-10 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 63.7 KB
2025-09-10 00:00
Regulatory News Service
기업설명회(IR)개최결과
Korean 6.7 KB
2025-07-17 00:00
Share Issue/Capital Change
기타주요경영사항(자율공시) (전환우선주의 보통주 전환)
Korean 7.8 KB
2025-04-23 00:00
Regulatory News Service
기업설명회(IR)개최결과
Korean 6.7 KB
2025-04-08 00:00
Share Issue/Capital Change
기타주요경영사항(자율공시) (전환우선주의 보통주 전환)
Korean 7.8 KB
2025-03-27 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 20.8 KB
2025-03-20 00:00
Pre-Annual General Meeting Information
주주총회집중일개최사유신고
Korean 4.9 KB
2025-03-18 00:00
Audit Report / Information
감사보고서제출
Korean 9.6 KB
2025-03-18 00:00
Annual / Quarterly Financial Statement
사업보고서 (2024.12)
Korean 342.5 KB
2025-03-12 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 261.5 KB
2025-03-07 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 12.8 KB
2025-03-07 00:00
Remuneration Information
[기재정정]주식매수선택권부여에관한신고
Korean 19.9 KB
2025-03-07 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 18.7 KB
2025-03-04 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 42.6 KB
2025-02-25 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 5.1 KB

Automate Your Workflow. Get a real-time feed of all AngioLab, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for AngioLab, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for AngioLab, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Nuvectis Pharma, Inc. Logo
Clinical-stage biopharma developing precision medicines for serious oncological conditions.
United States of America
NVCT
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway
NYKD
Ocugen, Inc. Logo
Develops gene/cell therapies and vaccines, specializing in blindness and public health.
United States of America
OCGN
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland
OCS
OKYO Pharma Ltd Logo
Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.
United States of America
OKYO
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea
244460
A technology platform for pharma/biotech to discover therapeutic antibodies via transgenic animals.
United States of America
OABIW
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea
382150
Onconic Therapeutics Inc. Logo
Develops novel drugs for cancer and GI diseases, including a next-gen acid blocker.
South Korea
476060
OncoTherapy Science, Inc. Logo
Develops targeted cancer therapies and provides TCR repertoire analysis services.
Japan
4564

Talk to a Data Expert

Have a question? We'll get back to you promptly.